33 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
25 Jun 24
Report of Foreign Private Issuer
4:31pm
of the Compensation, Nomination and Governance Committee
Proposal
The Board of Directors proposes that Ronald Hafner and Gian-Marco Rinaldi Diaz de … la Cruz shall be re-elected as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
6 Jun 24
Report of Foreign Private Issuer
5:00pm
of the members of the Compensation, Nomination and Governance Committee
Proposal
The Board of Directors proposes that Ronald Hafner and Gian-Marco Rinaldi Diaz … de la Cruz shall be re-elected as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary
424B5
NLSP
NLS Pharmaceutics Ltd
22 Mar 24
Prospectus supplement for primary offering
10:24am
, the members of the compensation, nomination and governance committee, the auditors and the independent proxy holder (a person annually elected by the general
6-K
EX-99.1
12bl9d16dx8wc6xmy5
9 Jun 23
Report of Foreign Private Issuer
8:30am
6-K
EX-99.1
z4e6 31b5uoi2liiw
11 May 22
Report of Foreign Private Issuer
5:00pm
424B5
thgmc4o8latx924l
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-99.1
qip7f6h
6 Apr 22
Investor Presentation | April 2022 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies
5:14pm
424B5
fpz23ewk medfve
4 Mar 22
Prospectus supplement for primary offering
4:01pm
F-3
7xkly
3 Feb 22
Shelf registration (foreign)
4:00pm
F-1
hvy56q6a78o22waxu
20 Dec 21
Registration statement (foreign)
4:06pm
F-1/A
wl05s 05xoypaldvo6m
1 Nov 21
Registration statement (foreign) (amended)
8:30am
F-1
tw93z97cmn4blxzo6
22 Oct 21
Registration statement (foreign)
4:02pm
POS AM
8gm ncxes25jhsw9ln7g
30 Sep 21
Prospectus update (post-effective amendment)
4:00pm
6-K
EX-99.1
argy d06j8k
6 Jul 21
Investor Presentation | July 2021 Alexander Zwyer, CEO & Co - Founder defining Central Nervous System Therapies
4:06pm